Insight into the Latest Developments in Oligonucleotide Delivery Systems

RNA Therapeutics Focus Day programme. End Quote

(1888PressRelease) November 04, 2019 - SMi Reports: A Focus Day has been added to SMi’s RNA Therapeutics Conference, which will highlight the recent developments in "Oligonucleotide Delivery Systems."

SMi Group are proud to present the new RNA Therapeutics Focus Day - Oligonucleotide Delivery Systems. The Focus Day will be held on the 18th of February 2020 and will present sessions that showcase a myriad of delivery approaches such as: optimising nanoparticle delivery to treat cancer and fibrosis; a review of common NA-LNP tolerability concerns to improve safety of nucleic acid therapeutics and the utility of light-triggered liposomes for retinal delivery.

In addition to this, delegates will have the opportunity to network with Global Product Managers, Heads of Drug Development, Senior Directors, Heads of Research and Development and many more.

As the only RNA therapeutics conference to dedicate a focus day to exploring developments and innovations in oligonucleotide delivery systems, the Oligonucleotide Delivery Systems Focus Day is a key diary date for those in the industry.

Focus Day Highlights:
Optimising Nanoparticle mediated delivery of siRNAs to treat cancer and fibrosis
• Presenting a polypeptide nanoparticle mediated delivery system for siRNA therapeutics to treat cancer and fibrosis
• The benefits of the ability to deliver multiple siRNAs within the tumour microenvironment
• Leveraging this capability to improve outcomes with Immune Checkpoint inhibitors
• Improved GMP manufacturing approaches using microfluidics for clinical development
David Evans, CSO, Sirnaomics

Addressing the challenge of chronic dosing via traditional LNPbased delivery for mRNA therapeutics
• Clinical appeal of lipid nanoparticle delivery systems and other competing modes of delivery
• Challenges in production and screening of LNP candidates for effective translation to biotherapeutics
• Complications of chronic dosing and acceptable tolerability profiles
• Showcasing the development of a tolerable subcutaneous administration of mRNA via functionalised LNPs
Shalini Andersson, Chief Scientist New Therapeutic Modalities, AstraZeneca

Exploring the development and progress of BioNTech mRNA therapeutic delivery platforms
• BioNtech’s approach to mRNA therapeutic delivery
• The mRNA oncology delivery platform
• Targeting the immune system via modified mRNA-encoding antigens
• Progress in protein-based replacement therapies to treat rare disease
• Current opportunities and challenges
Heinrich Haas, VP RNA Formulation & Drug Delivery, BioNTech

RNA Therapeutics
Focus Day: 18th February 2020
Conference: 19th – 20th February 2020
Copthorne Tara Hotel, London, UK

Proudly sponsored by:
ChemGenes | Thermo Fisher Scientific

###

space

Other Related Press Releases